Clinical Trials
23 trialsNCT03598998 2026-05-26
Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas
City of Hope Medical Center
Phase 1/2 Active not recruiting
NCT07225985 2026-05-11
Pralatrexate With Bendamustine and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma
Fred Hutchinson Cancer Center
Phase 1/2 Recruiting
NCT06874946 2026-05-07
Phase I/II
Peking University People's Hospital
Phase 1/2 Recruiting
NCT03035331 2026-05-04
Dendritic Cell Therapy, Cryosurgery, and Pembrolizumab in Treating Patients With Non-Hodgkin Lymphoma
Mayo Clinic
Phase 1/2 Completed
NCT07339527 2026-01-14
EZH2 Inhibitor Zeprumetostat in Combination Therapy for Patients With Relapsed or Refractory Mature T-cell and NK-cell Lymphomas
Sun Yat-sen University
Phase 1/2 Not yet recruiting
NCT03278782 2026-01-09
Study of Pembrolizumab (MK-3475) in Combination With Romidepsin
M.D. Anderson Cancer Center
Phase 1/2 Active not recruiting
NCT04074746 2025-09-30
Modified Immune Cells (AFM13-NK) and A Monoclonal Antibody (AFM13) in Treating Patients With Recurrent or Refractory CD30 Positive Hodgkin or Non-Hodgkin Lymphomas
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT03011814 2025-09-18
Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma
City of Hope Medical Center
Phase 1/2 Active not recruiting
NCT07117305 2025-08-12
CD7 CAR-T Combined With Autologous Hematopoietic Stem Cell Transplantation
Zhengzhou University
Phase 1/2 Not yet recruiting
NCT07022964 2025-06-15
CD5 CAR T-Cell Therapy for r/r T-cell Lymphomas
Beijing GoBroad Hospital
Phase 1/2 Recruiting
NCT06925464 2025-05-13
CD7 CAR T-Cell Therapy for r/r T-cell Lymphomas
Beijing GoBroad Hospital
Phase 1/2 Recruiting
NCT01701986 2025-02-28
Gemcitabine Hydrochloride, Clofarabine, and Busulfan Before Donor Stem Cell Transplant in Treating Patients With Refractory B-Cell or T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT06420076 2024-11-12
BAH246
Essen Biotech
Phase 1/2 Recruiting
NCT02341014 2024-04-04
Combination Therapy With Carfilzomib, Romidepsin, Lenalidomide in Patients With Relapsed or Refractory B- and T-cell Lymphomas
Memorial Sloan Kettering Cancer Center
Phase 1/2 Completed
NCT02561273 2023-12-13
Combination Chemotherapy & Lenalidomide in Newly Diagnosed Stage II-IV Peripheral T-cell Non-Hodgkin's Lymphoma
University of Nebraska
Phase 1/2 Completed
NCT05230680 2023-10-23
Azacitidine-CHOP for Patients With Nodal T-cell Lymphoma With T-follicular Helper Phenotype (ACANTUS)
Samsung Medical Center
Phase 1/2 Recruiting
NCT03192202 2023-07-20
AFM13 in Relapsed/Refractory Cutaneous Lymphomas
Columbia University
Phase 1/2 Completed
NCT03161223 2022-03-31
Durvalumab in Different Combinations With Pralatrexate, Romidepsin and Oral 5-Azacitidine for Lymphoma
University of Virginia
Phase 1/2 Recruiting
NCT04653649 2020-12-04
CAR T-cells Against CD30 (HSP-CAR30) for Relapsed/ Refractory Hodgkin and T-cell Lymphoma.
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Phase 1/2 Unknown
NCT01921387 2020-08-04
Radiolabeled Monoclonal Antibody and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With High-Risk Lymphoid Malignancies
Fred Hutchinson Cancer Center
Phase 1/2 Completed
NCT03044743 2017-05-02
PD-1 Knockout EBV-CTLs for Advanced Stage Epstein-Barr Virus (EBV) Associated Malignancies
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 1/2 Unknown
NCT02987244 2016-12-08
Chidamide Plus CHOEP Combined With Upfront ASCT in Untreated Peripheral T-cell Lymphoma
Peking Union Medical College Hospital
Phase 1/2 Unknown
NCT01198665 2015-03-03
RADCHOP
Samsung Medical Center
Phase 1/2 Completed